There is disclosed a method for authentication between a first party and a second party. The method comprises: generating a current shared key by exchanging one or more messages between the first and second parties; and authenticating the current shared key based on a previously authenticated shared key. In some examples, the current shared key may be authenticated based on both the previously authenticated shared key and the current shared key, and/or based on at least one secret value obtained by the first party and/or the second party. In some examples, authenticating the current shared key may comprise exchanging one or more messages between the first and second parties, wherein at least one of the messages is generated based on one or more of: the current shared key; the previously authenticated shared key; and the at least one secret value. In some examples, when the current shared key is determining to be authenticated, the current shared key may be stored to be used as a previously authenticated shared key when authenticating a new current shared key.
G06F 21/30 - Authentication, i.e. establishing the identity or authorisation of security principals
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
The invention relates to a method, particularly a computer-implemented method for estimating a flow profile of a fluid flow in a vessel comprising the steps of: - Acquiring a series of ultrasonic signal data comprising information on a fluid flow in the vessel, - Identifying a shadowed region in the ultrasonic signal data, that is devoid of information on the fluid flow in the vessel. - Determining a flow profile of the fluid from the ultrasonic signal data for flow regions of the vessel outside the shadowed region, - Estimating the flow profile in the shadowed region with a physics-informed machine learning method that is trained with flow data comprising information on the flow profile determined for the flow regions outside the shadowed region and location data comprising a plurality of locations in and/or outside the shadowed region and associated time points.
The invention relates to a method for determining a velocity of a fluid and/or a pressure distribution in a vessel, the method comprising the steps of: - Acquiring a series of ultrasonic signal data comprising information on tracers comprised by a fluid flow in a vessel, - Three-dimensionally localizing and tracking at least some of the tracers in the series of the ultrasonic signal data, such that for each tracked tracer flow data is obtained, the flow data comprising information on a plurality of locations and associated velocities at different time points of the tracer, - From the locations of the tracers, determining, particularly segmenting a flow volume delimiting a volume within which the fluid flow takes place in the vessel, - Estimating the velocity and/or the pressure for at least one time point of the fluid in the vessel with a physics-informed machine learning method that is trained with at least some of the flow data and with location data, wherein the location data comprises a plurality of locations within the flow volume and associated time points.
The present invention relates to compounds of formula (I): wherein R1is a dye, and L', R2and R3 are as defined herein. The compounds of the invention reversibly convert from a hydrophobic form to a hydrophilic form upon contact with water and carbon dioxide. The present invention also relates to methods of dyeing fibres, and methods of decolouring dyed fibres. The method is particularly useful for dyeing polyester fibres.
C09B 1/26 - Dyes with amino groups substituted by hydrocarbon radicals
C09B 1/32 - Dyes with amino groups substituted by hydrocarbon radicals substituted by aryl groups
C09B 1/515 - N-alkyl, N-aralkyl, or N-cycloalkyl derivatives
C09B 43/44 - Preparation of azo dyes from other azo compounds by substituting amine groups for hydroxyl groups or hydroxy groups for amine groupsDesacylation of amino-acyl groupsDeaminating
C09B 1/20 - Preparation from starting materials already containing the anthracene nucleus
C09B 57/00 - Other synthetic dyes of known constitution
C09B 5/24 - Dyes with an anthracene nucleus condensed with one or more heterocyclic rings with or without carbocyclic rings the heterocyclic ring(s) being condensed with an anthraquinone nucleus in 1-2 or 2-3 position
C07D 265/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
The invention relates to tribological composites comprising diamond-like carbon and carbonaceous multi-layered nanoparticulate, e.g. graphene nanoplatelets, and methods for their preparation.
C23C 16/50 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges
F16C 33/12 - Structural compositionUse of special materials or surface treatments, e.g. for rust-proofing
A method of increasing or decreasing the auxetic response strain-threshold of an aligned nematic liquid crystal elastomer comprising chemically modifying the aligned nematic liquid crystal elastomer.
C09K 19/04 - Liquid crystal materials characterised by the chemical structure of the liquid crystal components
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
A composite comprises a plurality of particles interspersed within an elastomer, wherein the elastomer is an auxetic aligned nematic liquid crystal elastomer. Another composite comprises first and second outer layers and an interlayer between the first and second outer layers, wherein the interlayer comprises an auxetic aligned nematic liquid crystal elastomer.
C09K 19/04 - Liquid crystal materials characterised by the chemical structure of the liquid crystal components
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
C09K 19/52 - Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives
8.
ANALYTE SENSOR WITH SEMI-TRANSPARENT MIRROR FOR ACHIEVING A LONG-RANGE INTERACTION BETWEEN ANALYTE AND A FLUORESCENT SUBSTANCE, AND CORRESPONDING METHOD
A device (100) to non-invasively determine a concentration of an analyte in a sampling volume (126) has a pulsed light source (114). A doped glass (104) has dopants that can emit fluorescence in a fluorescence wavelength range that at least partially overlaps with an absorption wavelength range of the analyte. The fluorescence has a first temporal fluorescence emission distribution in response to optical excitation by the pulsed light source (114) when the analyte concentration in the sampling volume is zero. A semi- transparent mirror (108) is interposed between the doped glass (104) and the sampling volume (126), such that the dopants emit fluorescence having a second temporal fluorescence emission distribution that is a function of the concentration of the analyte in the sampling volume (126). A detector (120) is configured to measure the second temporal fluorescence emission distribution such that the concentration of the analyte in the sampling volume (126) can be determined based on a change between the first temporal fluorescence emission distribution and the second temporal fluorescence emission distribution.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
9.
METHOD OF PREPARING AN ALIGNED LIQUID CRYSTAL ELASTOMER
A method of preparing method of preparing an aligned nematic liquid crystal elastomer with a reduced auxetic response threshold comprising applying a pre-strain condition to a liquid crystal elastomer.
C09K 19/04 - Liquid crystal materials characterised by the chemical structure of the liquid crystal components
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
: Apparatus and method to prepare a sample for cryo-electron microscopy (cryo-EM). The sample preparation system comprises at least one deposition nozzle fluidically connectable to a sample and a propellant gas to create a stream of sample droplets. The substrate is mountable immediately below a gas-liquid interface of a cryogen such that the stream of sample droplets is configured to temporarily displace the cryogen from the substrate to allow vitrification of the sample at a surface of the substrate.
An electrocaloric device based on a liquid material suitable for cooling and heat management. The liquid crystalline material designated for the device is operated in or in vicinity of the ferroelectric nematic phase. The device has broad operating temperature, high induced temperature change, while requiring modest electric field strengths.
The present invention contemplates the formation of poly(amino acids) via a 2,5-diketopiperazine intermediate. The 2,5-diketopiperazine undergoes a ring-opening polymerisation reaction to afford the corresponding poly(amino acid).
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C08G 69/00 - Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
Ultrasound beamforming is performed by a deep learning architecture incorporating convolution layers and known operators. The network is trained to combine multiple observations of complex signal data in an optimal way into a single complex signal. This is achieved using convolutional layers with learnable parameters and by embedding and an operator to perform multiple weighted sum operations of subsets of the original observations and average these to produce a single complex signal. Known operators including a forward-backward operator are optionally incorporated into the architecture.
Ultrasound beamforming is performed by a deep learning architecture incorporating convolution layers and known operators. The network is trained to combine multiple observations of complex signal data in an optimal way into a single complex signal. This is achieved using convolutional layers with learnable parameters and by embedding and an operator to perform multiple weighted sum operations of subsets of the original observations and average these to produce a single complex signal. Known operators including a forward-backward operator are optionally incorporated into the architecture.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
SINAI HEALTH SYSTEM (Canada)
DREXEL UNIVERSITY (USA)
THE WISTAR INSTITUTE (USA)
UNIVERSITY OF LEEDS (United Kingdom)
Inventor
Greenberg, Roger
Sicheri, Frank
Zeqiraj, Elton
Salvino, Joseph M.
Abstract
The present disclosure provides for techniques using BRISC deubiquitinating enzyme inhibitors of formula (I) for treating and/ or preventing systemic lupus erythematosus (SLE). Accordingly, the present disclosure provides for compositions and methods for treating or preventing a disease or disorder mediated by inhibition of type I interferon receptor (IFNAR1) signaling.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
The invention relates to a method of identifying a genomic target for a test stimulus that is capable of modulating a cell phenotype, comprising: a) providing a population of cells that are phenotypically negative in response to the test stimulus; b) modifying the population of cells by random insertion into the cell genome of a gain-in-function construct; c) contacting the modified cell population with the test stimulus; d) screening the exposed modified cell population to identify modified cells that are phenotypically positive in response to the test stimulus; and e) identify a gene or genes associated with said positive phenotype thereby identifying the genomic target of the test stimulus.
There is provided a computer-implemented method for generating virtual chimera populations of multi-part organ shapes for use in an in-silico trial, wherein organ shapes are represented as surface or volumetric meshes, the method comprising using a part-aware generative model to learn a latent representation of each part of a multi-part organ shape for inclusion in a virtual population and output synthesised parts of the multi-part organ shape, using a spatial composition model to align the outputted synthesised parts of the multi-part organ shape and output an anatomically meaningful example of an overall multi-part organ shape as a virtual chimera and storing the virtual chimera in the virtual population, for use in the in-silico study. There is also provided an apparatus and computer readable medium embodying the method.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Examples provide a multilevel switched-mode ultrasound transmitter comprising a first push-pull transistor arrangement comprising first and second drive transistors, third and fourth additional switched transistors, each arranged as a bidirectional load switch with a one of the first and second drive transistors, wherein the first drive transistor and associated third additional switched transistor operate in series as a first arm of the first push-pull transistor arrangement, and the second drive transistor and associated fourth additional switched transistor operate in series as a second arm of the first push-pull transistor arrangement, wherein each arm is coupled between a respective polarity instance of a first bipolar drive voltage supply and a common output.
This invention relates to a food product comprising an additive formulation, the additive formulation comprising a proteinaceous microgel and a biopolymeric hydrogel. The invention also relates to methods for preparing such food products. The invention also relates to a use of an additive formulation as a fat replacement and/or an astringency reducer and/or a mouthfeel enhancer, the additive formulation comprising a proteinaceous microgel and a biopolymeric hydrogel.
A23L 27/00 - SpicesFlavouring agents or condimentsArtificial sweetening agentsTable saltsDietetic salt substitutesPreparation or treatment thereof
A23L 29/269 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
ABAA iBB iABAA iAAA iAA iABB iBBB iBB iAA iand VBiAAA iBBB i for which the condition is satisfied. The method may further comprise: repeating the steps of determining, exchanging and obtaining a reduced data set one or more times until one or more termination criteria are satisfied, wherein the data sets used in one iteration comprise the reduced data sets obtained in the preceding iteration.
An implantable device for monitoring an intra-articular joint environment corresponding to a joint body, for example a bone or a prosthetic joint component. The implantable device comprises: a sensor module configured to measure data indicative of at least one parameter of an intra-articular joint environment corresponding to a joint body; a communications unit operatively coupled to the sensor module and configured to transmit the measured data to an external device; and a rechargeable battery configured to power the sensor module and the communications unit, wherein the sensor module, the power supply and the communications unit are contained within a capsule, wherein the capsule is releasably mountable within an opening of the joint body, and wherein, when the capsule is releasably mounted within the opening of the joint body, the sensor module is configured to monitor the at least one parameter of the intra-articular joint environment.
A system for powering a device, the system comprising: a wireless power transmitter configured to transmit a first power signal, and a receiver unit configured to: receive the first power signal, convert the first power signal to a second power signal for wirelessly powering a device, and transmit the second power signal to power the device through inductive coupling.
H02J 50/15 - Circuit arrangements or systems for wireless supply or distribution of electric power using ultrasonic waves
H02J 50/20 - Circuit arrangements or systems for wireless supply or distribution of electric power using microwaves or radio frequency waves
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02J 50/50 - Circuit arrangements or systems for wireless supply or distribution of electric power using additional energy repeaters between transmitting devices and receiving devices
24.
Systems and Methods for Probabilistic Forecasting of Extremes
A computer-implemented method for producing probabilistic forecasts of extreme values. The method comprises obtaining input data comprising a plurality of signals of interest and a plurality of covariates associated therewith, each covariate of the plurality of covariates having an associated data type. The method further comprises performing a first forecast based on the input data. Performing the first forecast comprises: obtaining one or more trained machine learning models, each trained machine learning model of the one or more trained machine learning models having been trained to map one or more covariates of a respective data type to one or more surrogate covariates; mapping, using the one or more trained machine learning models and the input data, the plurality of covariates to one or more surrogate covariates, the one or more surrogate covariates corresponding to a compressed representation of the input data; fitting a statistical model of extremes to the plurality of signals of interest and the one or more surrogate covariates thereby generating a fitted statistical model of extremes, the statistical model of extremes being defined according to a predetermined distribution having a plurality of parameters; and obtaining a probabilistic forecast of future extreme values based on the fitted statistical model of extremes for one or more future time steps. The method further comprises causing control of a controllable system based at least in part on the probabilistic forecast of future extremes.
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
25.
SYSTEMS AND METHODS FOR PROBABILISTIC FORECASTING OF EXTREMES
A computer-implemented method for producing probabilistic forecasts of extreme values. The method obtains input data comprising a plurality of signals of interest and a plurality of covariates associated therewith, each covariate having an associated data type. Performing a first forecast comprises: obtaining one or more trained machine learning models, each trained machine learning model having been trained to map one or more covariates of a respective data type to one or more surrogate covariates; the one or more surrogate covariates corresponding to a compressed representation of the input data; fitting a statistical model of extremes to the plurality of signals of interest and the one or more surrogate covariates; and obtaining a probabilistic forecast of future extreme values and further causing control of a controllable system based at least in part on the probabilistic forecast of future extremes.
G06Q 10/04 - Forecasting or optimisation specially adapted for administrative or management purposes, e.g. linear programming or "cutting stock problem"
26.
SPLIT REPORTER COMPLEX FOR PROTEIN-COMPLEMENTATION ASSAYS
G01N 33/535 - Production of labelled immunochemicals with enzyme label
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A computer-implemented method for determining cardiac functional indices for a patient comprising: receiving an image of a fundus of the patient; encoding the received image into a joint latent space; decoding from the joint latent space a representation of the patient's heart; providing the representation decoded from the joint latent space to a neural network configured to generate cardiac functional indices; and outputting the cardiac functional indices generated by the neural network in response to receiving the decoded representation of the patient's heart.
The present application discloses a climbing robot (10) for climbing ferrous structures (30), a dual gear pivot mechanism for a climbing robot (10), and a method of controlling a climbing robot (10) for climbing ferrous structures (30). The climbing robot (10) comprises three drive units (12, 14, 16) coupled together and the central drive unit is coupled to a pivot mechanism (24). Each drive unit (12, 14, 16) comprises a wheel arrangement (13, 15, 17) comprising at least one wheel configured to adhere to a ferrous tower (30), and each wheel is independently controllable. A first wheel arrangement (13) is the wheel arrangement of one of the three drive units (12,14, 16). A second wheel arrangement (15) is the wheel arrangement of another one of the three drive units (12, 14, 16). The pivot mechanism (24) is arranged to change the average distance between the first and second wheel arrangements (13, 15) in response to movement, about a point of the pivot mechanism (24) by an angle, of the two end drive units (12, 16) with respect to each other.
B62D 57/024 - Vehicles characterised by having other propulsion or other ground-engaging means than wheels or endless track, alone or in addition to wheels or endless track with ground-engaging propulsion means, e.g. walking members specially adapted for moving on inclined or vertical surfaces
The invention relates to genetically altered plants with improved traits, in particular steeper root growth. The invention also relates to methods for making such plants and methods for modulating root growth, in particular methods that employ gene editing techniques.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
The present invention relates to method of identifying a selective BRISC inhibitor. The present invention also relates to a stable BRISC dimer. The present invention further relates to use of the stable BRISC dimer to generate cryo-Electron Microscopy (cryo-EM), crystallography, nuclear magnetic resonance and/or X-ray crystallography structures for structure guided drug design.
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G01N 23/20008 - Constructional details of analysers, e.g. characterised by X-ray source, detector or optical systemAccessories thereforPreparing specimens therefor
THE UNIVERSITY OF LEEDS, a body incorporated by Royal Charter (RC: 000658) (United Kingdom)
Inventor
Vorobieva, Anastassia
Baker, David
Horne, James Ea
Abstract
The present disclosure provides non-naturally occurring beta barrel proteins as defined, self-complementing multipartite beta barrel proteins, uses of such proteins, and methods for designing such proteins.
Methods allowing prediction of a response to anti-EGFR therapies are provided, which include histochemical or cytochemical staining methods for staining amphiregulin (AREG) or epiregulin (EREG). Scoring algorithms are provided that may include but are not limited to determining a percent tumor cell positivity for each of EREG and AREG and comparing the determined percent positivity to pre-determined cut offs. The pre-determined cut offs can be either positive cut offs (in which case patients are treated with the EGFR-directed therapy if the percentage is greater than or equal to the cut off), negative cut offs (in which case patients are not treated with the EGFR-directed therapy if the percentage is less than the cut off), or both a positive and negative cut off.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
33.
Test Slides and Methods of Production in Stain Assessment
A QA test slide for use in a stain QA method for a stain and method of making QA test slides are described. The QA test slide comprises: a transparent substrate; a piece of biopolymer material mounted on the transparent substrate; and a sticker defining an aperture and adhered to the transparent substrate over the piece of biopolymer material and with a portion of the piece of biopolymer material exposed by the aperture and wherein a machine readable code is borne by the sticker and the machine readable code encodes a unique identifier for the QA test slide.
Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Magnetic shape-forming surgical continuum manipulator (“CM”) comprising an elastomeric base material and a plurality of magnetic elements, the plurality of magnetic elements being located at a plurality of points along a length of the CM and each magnetic element having a predetermined magnetic profile, whereby the shape of the CM can be magnetically manipulated substantially along said length by the application of an external magnetic field and a magnetic field gradient.
A carrier molecule for the detection of a target analyte comprises a molecular frame which defines a central void, and a binding moiety which is specific for the target analyte. The binding moiety is bound to the frame and positioned such that the target analyte, when bound to the binding moiety, is located in the central void. The carrier molecule finds use in the detection and/or quantification of target analytes in a sample.
The invention relates to tribological composites comprising diamond-like carbon and carbonaceous multi-layered nanoparticulate, e.g. graphene nanoplatelets, and methods for their preparation.
Provided is 4-methylumbelliferone, derivatives and salts thereof, or a composition comprising same for use in the treatment of a condition of the nervous system in a subject. Preferably, the condition is one associated with a scar, such as a glial scar. Typically, the condition of the nervous system is selected from the group comprising conditions caused by trauma, injury, infection, degeneration, structural defects, tumours, blood flow disruption. The neural and other lesions are made permeable and repairable.
C07D 311/16 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.
This invention relates to compounds of formula (I) and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
This invention relates to: a composition comprising a chitosan gel as the primary component, wherein the composition comprises: (i) an iron-doped calcium phosphate mineral component; and (ii) a collagen component; to a freeze-dried composition comprising a chitosan gel as the primary component, wherein the composition comprises: (i) an iron-doped calcium phosphate mineral component; and (ii) a collagen component that has been subjected to one or more processing steps to remove solvents; a bone scaffold in which a first layer comprises a porous titanium/TiO2-based composition and a second layer comprises the freeze dried composition of the invention; and methods of manufacturing these compositions, freeze dried compositions and bone scaffolds.
A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
The invention relates to a method of identifying a genomic target for a test stimulus that is capable of modulating a cell phenotype, comprising: a) providing a population of cells that are phenotypically negative in response to the test stimulus; b) modifying the population of cells by random insertion into the cell genome of a gain-in-function construct; c) contacting the modified cell population with the test stimulus; d) screening the exposed modified cell population to identify modified cells that are phenotypically positive in response to the test stimulus; and e) identify a gene or genes associated with said positive phenotype thereby identifying the genomic target of the test stimulus.
The Board of Trustees of the Leland Stanford Junior University (USA)
The University of Leeds (United Kingdom)
University of Konstanz (Germany)
Inventor
Frydman, Judith
Radford, Sheena E.
Deuerling, Elke
Abstract
Compositions and methods for treating aggregation-associated diseases are disclosed. In particular, compositions comprising the nascent polypeptide-associated complex (NAC) and the apical domain of CCT1 as well as peptide fragments thereof and fusion proteins containing NAC and CCT1 peptides can be used to suppress pathological protein aggregation and are useful for treatment of diseases associated with polyQ aggregation, amyloid beta aggregation, and alpha-synuclein aggregation.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
There is provided the use of an aligned nematic elastomer to form a material having auxetic properties wherein the aligned nematic material has a mechanical Fréedericksz transition. Also provided is a method of producing an aligned nematic elastomer for said use.
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
C09K 19/54 - Additives having no specific mesophase
Examples provide a multilevel switched-mode ultrasound transmitter comprising a first push-pull transistor arrangement comprising first and second drive transistors, third and fourth additional switched transistors, each arranged as a bidirectional load switch with a one of the first and second drive transistors, wherein the first drive transistor and associated third additional switched transistor operate in series as a first arm of the first push-pull transistor arrangement, and the second drive transistor and associated fourth additional switched transistor operate in series as a second arm of the first push-pull transistor arrangement, wherein each arm is coupled between a respective polarity instance of a first bipolar drive voltage supply and a common output.
B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
H02M 7/483 - Converters with outputs that each can have more than two voltage levels
H02M 7/538 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a push-pull configuration
H03F 3/217 - Class D power amplifiersSwitching amplifiers
H03K 17/10 - Modifications for increasing the maximum permissible switched voltage
THE LEEDS AND BRADFORD BOILER COMPANY LIMITED (United Kingdom)
THE UNIVERSITY OF LEEDS (United Kingdom)
Inventor
Burkle, Daniel Phillip
Jacklin, Robert Anthony
Abstract
A device for use in testing a sealed environment comprises a shaft (108) and a housing (110) surrounding, and extending at least part of the length of, the shaft. The housing defines a cavity and there is a dynamic seal (119) between the shaft and the housing, and an environment isolation seal (102) mounted to the shaft. The shaft is axially slidable with respect to the housing and the dynamic seal.
Examples provide a multilevel switched-mode ultrasound transmitter comprising a first push-pull transistor arrangement comprising first and second drive transistors, third and fourth additional switched transistors, each arranged as a bidirectional load switch with a one of the first and second drive transistors, wherein the first drive transistor and associated third additional switched transistor operate in series as a first arm of the first push-pull transistor arrangement, and the second drive transistor and associated fourth additional switched transistor operate in series as a second arm of the first push-pull transistor arrangement, wherein each arm is coupled between a respective polarity instance of a first bipolar drive voltage supply and a common output.
H03K 17/10 - Modifications for increasing the maximum permissible switched voltage
H03F 3/217 - Class D power amplifiersSwitching amplifiers
B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy
H02M 7/538 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a push-pull configuration
H02M 7/483 - Converters with outputs that each can have more than two voltage levels
A method of assessing a wound in a subject is provided. The method comprises obtaining one or more optical coherence tomography images of the wound and analysing the one or more optical coherence tomography images using a deep learning model that has been trained to classify pixels in an optical coherence tomography image of a wound between a plurality of classes comprising a plurality of classes associated with different types of wound tissue, thereby obtaining for each image analysed, an indication of the location of tissue likely to belong to each of the different types of wound tissue in the respective image.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
49.
PREDICTION OF RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-DIRECTED THERAPIES USING EPIREGULIN AND AMPHIREGULIN
Methods allowing prediction of a response to anti-EGFR therapies are provided, which include histochemical or cytochemical staining methods for staining amphiregulin (AREG) or epiregulin (EREG). Scoring algorithms are provided that may include but are not limited to determining a percent tumor cell positivity for each of EREG and AREG and comparing the determined percent positivity to pre-determined cut offs. The pre-determined cut offs can be either positive cut offs (in which case patients are treated with the EGFR-directed therapy if the percentage is greater than or equal to the cut off), negative cut offs (in which case patients are not treated with the EGFR-directed therapy if the percentage is less than the cut off), or both a positive and negative cut off.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A catalytic converter including a catalyst, the catalyst comprising a material of olivine composition, an engine comprising this catalytic converter and an method of producing nitrogen from NOx comprising the catalytic reduction of NOx by a catalyst comprising of a material of olivine composition. In addition, the use of a material of olivine composition in a catalytic reduction of NOx and a method of manufacture of a catalytic converter comprising adding the catalyst to a wash coat, applying the catalyst containing wash coat to a substrate and annealing the coated substrate.
F01N 3/20 - Exhaust or silencing apparatus having means for purifying, rendering innocuous, or otherwise treating exhaust for rendering innocuous by thermal or catalytic conversion of noxious components of exhaust characterised by methods of operationControl specially adapted for catalytic conversion
THE UNIVERSITY OF LEEDS, A BODY INCORPORATED BY ROYAL (United Kingdom)
Inventor
Vorobieva, Anastassia
Baker, David
Horne, James, Ea
Abstract
The present disclosure provides non-naturally occurring beta barrel proteins as defined, self-complementing multipartite beta barrel proteins, uses of such proteins, and methods for designing such proteins.
Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.
The present invention relates to virus like particles, vaccines and delivery vectors utilising coronavirus packaging signals, and therapeutic agents targeting such packaging signals.
1222)xOH where x may be 1 – 5; to methods of manufacture, intermediates, and uses thereof; and a textile product, sanitary product and a flame retardant textile comprising said triazine compound.
The present application relates to a method for the production of a noble metal nanomaterial comprising: (A) adding an aqueous solution of a source of noble metal ions and a reducing agent to an aqueous solution of an organic compound to form a reaction mixture, wherein the organic compound is capable of undergoing 2D planar stacking in aqueous solution; and (B) separating the noble metal nanomaterial from the reaction mixture. The present application also relates to a noble metal nanomaterial manufactured according to said method.
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
This invention relates to a formulation comprising a proteinaceous microgel and one or more biopolymeric nanofibrils. The invention also relates to methods for preparing such formulations. The invention also contemplates the uses of the formulations.
A scanner for scanning a QA test slide as part of a stain QA method, and method of using the scanner are described. The scanner comprises a housing defining an interior of the scanner, a slide holder within the housing and configured to receive a QA test slide, a digital camera within the housing and arranged to capture an image of the QA test slide when located in the slide holder, and a light source within the housing and arranged to illuminate both a rear side and a front side of the QA test slide when located in the slide holder.
A QA test slide for use in a stain QA method for a stain and method of making QA test slides are described. The QA test slide comprises: a transparent substrate; a piece of biopolymer material mounted on the transparent substrate; and a sticker defining an aperture and adhered to the transparent substrate over the piece of biopolymer material and with a portion of the piece of biopolymer material exposed by the aperture and wherein a machine readable code is borne by the sticker and the machine readable code encodes a unique identifier for the QA test slide.
A method for determining the quality of a stain as part of a stain quality assurance method for the stain. The method is carried out by a data processing device and comprises: determining R, G and B values for a portion of an image of a test slide corresponding to a piece of biopolymer material that has been stained using the stain; converting the R, G and B values into corresponding values for L, A and B in an LAB colour space; determining a distance in the LAB colour space between the L, A and B values and reference values for L, A and B; using the distance in the LAB colour space to determine the quality of the stain; and outputting an indication of the quality of the stain.
A stain quality assurance method for a stain and a stain QA system are described. The stain quality assurance method for a stain comprises: staining a QA test slide using a stain being or to be used to stain sample slides; capturing an image of the stained QA test slide; and processing the image to determine the quality of the stain. The stain QA system comprises: a plurality of QA test slides; a QA test slide scanner configured to capture an image of a QA test slide; and a data processing device configured to process the image of the QA test slide to determine the quality of a stain that has been applied to the QA test slide.
The invention relates to a composite material comprising cellulose. The composite material comprises a first cellulose-based material, which may be a textile or fabric, and a second cellulose-based material, which may be a film or cellulose based material or powdered cellulose-based material. The second cellulose-based material may be a sheet material comprising cellulose, such as a paper or a regenerated cellulose film. In embodiments the material is a so called “all cellulose composite” where both of the materials that are brought together are different forms of material comprising or being cellulose. For example, the different materials originate from cellulose-based feedstocks. The invention also relates to a process for preparing the composite materials of the invention utilising ionic liquids.
B31F 1/00 - Mechanical deformation without removing material, e.g. in combination with laminating
B31F 1/36 - Moistening and heating webs to facilitate mechanical deformation and drying deformed webs
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 23/06 - Layered products essentially comprising cellulosic plastic substances comprising such substance as the main or only constituent of a layer, next to another layer of a specific substance of paper or cardboard
A carrier molecule for the detection of a target analyte comprises a molecular frame which defines a central void, and a binding moiety which is specific for the target analyte. The binding moiety is bound to the frame and positioned such that the target analyte, when bound to the binding moiety, is located in the central void. The carrier molecule finds use in the detection and/or quantification of target analytes in a sample.
The present invention provides a method of preparing a sample comprising one or more proteins of interest, the method comprising: providing a sample comprising a population of proteins of interest solubilised with a surfactant in a medium; exposing said sample to a mild precipitant to cause precipitation of said proteins; during or after the precipitation step, bringing said sample into contact with a matrix adapted to capture said precipitated proteins and prevent excessive aggregation of precipitated protein particles; and washing the matrix with captured precipitated proteins to remove the surfactant. A sample preparation device to carry out the same is also provided.
A process for reducing microbial growth in solutions of sugars extracted from waste materials, the process comprising monitoring indicators of microbial growth in the solution in situ and administering an antimicrobial; a sugar substrate obtained by concentrating a solution of sugar treated using the process; an apparatus for extracting sugars from waste materials, the apparatus comprising a reaction vessel (10), one or more sensors (15,20) for monitoring indicators of microbial growth in the reaction vessel, a software for analysing signals from the sensor and a source of antimicrobial.
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C13B 10/12 - Details of extraction apparatus, e.g. arrangements of pipes or valves
C13B 50/00 - Sugar products, e.g. powdered, lump or liquid sugarWorking-up of sugar
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ GRENOBLE ALPES (France)
Inventor
Richter, Ralf Peter
Frost, Anders Rickard
Debarre, Delphine
Jana, Saikat
Abstract
A surface force apparatus (SFA) comprises a first pressing member (2) presenting a convex first bearing surface having a radius of curvature, and a second pressing member (3) presenting a second bearing surface. At least one of the first and second bearing surfaces comprises an external surface configured to receive thereupon a film of material for immersion in a bulk solvent fluid thereby to be solvated by molecules from the bulk solvent fluid. A manipulator with a pivot arm (11) is configured to move at least one of the first and second pressing members to cause the first and second bearing surfaces to bear against each other with a substantially constant and static urging force. Consequently, parts of a said film occupy a gap thereby formed between the first and second bearing surfaces which expels bulk solvent fluid. The ratio (F/R) of the magnitude (F) of the urging force and the radius of curvature (R) of the first bearing surface is in the range 2.0 N/m to 100.0 N/m. The film is imaged with a microscope.
A device for supporting development of a cellular deposit comprising at least one of a cell or a tissue derived from an ovary. The device comprises an inlet well, an outlet well, and an enclosed culture chamber disposed between the inlet well and the outlet well. The device further comprises an inlet channel fluidly coupling the inlet well to the culture chamber and an outlet chamber and/or at least one outlet channel fluidly coupling the culture chamber to the outlet well. At least one of the outlet chamber and the at least one outlet channel is sized to prevent passage of the cellular deposit therethrough.
The present specification relates to (S)-2-(l-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2- yl)piperidin-3-yl)acetic acid (AZD4017), or a pharmaceutically acceptable salt thereof, for oral use in the treatment or prophylaxis of wounds, for example in diabetic patients. Methods of treatment and prophylaxis and the use of the compound in the preparation of a medicament for the treatment and prophylaxis of wounds are also provided.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
68.
(S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine
The present specification relates to (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid (AZD4017), or a pharmaceutically acceptable salt thereof, for oral use in the treatment or prophylaxis of wounds, for example in diabetic patients. Methods of treatment and prophylaxis and the use of the compound in the preparation of a medicament for the treatment and prophylaxis of wounds are also provided.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C04B 35/495 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides based on vanadium, niobium, tantalum, molybdenum or tungsten oxides or solid solutions thereof with other oxides, e.g. vanadates, niobates, tantalates, molybdates or tungstates
C04B 35/626 - Preparing or treating the powders individually or as batches
The invention relates to genetically altered plants with improved traits, in particular steeper root growth. The invention also relates to methods for making such plants and methods for modulating root growth, in particular methods that employ gene editing techniques.
C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
The invention relates to genetically altered plants with improved traits, in particular steeper root growth. The invention also relates to methods for making such plants and methods for modulating root growth, in particular methods that employ gene editing techniques.
A three-dimensional (3D) dental scanning system (1) for scanning a dental object (D) includes a scanning surface (124a) to support the dental object (D); a scanning section (130) to capture a 3D scan of the dental object (D); a motion section (120) to move the scanning surface (124a) and scanning section (130) relative to each other in five axes of motion, whilst retaining the scanning surface (124a) in a substantially horizontal plane, and a control unit (140) configured to control the motion section (120) and the scanning section (130) to obtain a 3D scan of the dental object (D).
A three-dimensional (3D) dental scanning system (1) for scanning a dental object (D) includes a scanning surface (124a) to support the dental object (D); a scanning section (130) to capture a 3D scan of the dental object (D); a motion section (120) to move the scanning surface (124a) and scanning section (130) relative to each other in five axes of motion, whilst retaining the scanning surface (124a) in a substantially horizontal plane, and a control unit (140) configured to control the motion section (120) and the scanning section (130) to obtain a 3D scan of the dental object (D).
A method includes providing a plurality of simulation components (101-105), each simulating operation of a distinct element of a cyber-physical system and including at least first and second simulation components (101, 102) arranged in series with one or more outputs of the first simulation component (101) being provided as input to the second simulation component (102). A plurality of output predictions are generated using a surrogate model of the first simulation component and, in response, a plurality of the second simulation components (102-1, 102-2, 102-3), or a plurality of second surrogate models, are executed in parallel. The input values of each second simulation component (102-1, 102-2, 102-3), or surrogate model corresponds to a respective one of the plurality of output predictions from the surrogate model of the first simulation component (101). Upon completion of execution of the first simulation component (10), a correct prediction of the plurality of output predictions is determined, the correct output prediction corresponding to an actual output of the first simulation component (101) at completion. In response, one or more of the plurality of second simulation components (102-1, 102-2, 102-3) or surrogate models not corresponding to the correct prediction are discarded.
G06F 30/20 - Design optimisation, verification or simulation
G06F 30/27 - Design optimisation, verification or simulation using machine learning, e.g. artificial intelligence, neural networks, support vector machines [SVM] or training a model
A method includes providing a plurality of simulation components (101-105), each simulating operation of a distinct element of a cyber-physical system and including at least first and second simulation components (101, 102) arranged in series with one or more outputs of the first simulation component (101) being provided as input to the second simulation component (102). A plurality of output predictions are generated using a surrogate model of the first simulation component and, in response, a plurality of the second simulation components (102-1, 102-2, 102-3), or a plurality of second surrogate models, are executed in parallel. The input values of each second simulation component (102-1, 102-2, 102-3), or surrogate model corresponds to a respective one of the plurality of output predictions from the surrogate model of the first simulation component (101). Upon completion of execution of the first simulation component (10), a correct prediction of the plurality of output predictions is determined, the correct output prediction corresponding to an actual output of the first simulation component (101) at completion. In response, one or more of the plurality of second simulation components (102-1, 102-2, 102-3) or surrogate models not corresponding to the correct prediction are discarded.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF LEEDS (United Kingdom)
UNIVERSITY OF KONSTANZ (Germany)
Inventor
Frydman, Judith
Radford, Sheena, E.
Deuerling, Elke
Abstract
Compositions and methods for treating aggregation-associated diseases are disclosed. In particular, compositions comprising the nascent polypeptide-associated complex (NAC) and the apical domain of CCT1 as well as peptide fragments thereof and fusion proteins containing NAC and CCT1 peptides can be used to suppress pathological protein aggregation and are useful for treatment of diseases associated with polyQ aggregation, amyloid beta aggregation, and alpha-synuclein aggregation.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
77.
Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A catalytic converter including a catalyst,the catalyst comprising a material of olivine composition, an engine comprising this catalytic converter and an method of producing nitrogen from NOx comprising the catalytic reduction of NOx by a catalyst comprising of a material of olivine composition. In addition, the use of a material of olivine composition in a catalytic reduction of NOx and a method of manufacture of a catalytic converter comprising adding the catalyst to a wash coat, applying the catalyst containing wash coat to a substrate and annealing the coated substrate.
B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
B01J 23/78 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with alkali- or alkaline earth metals or beryllium
B01D 53/94 - Chemical or biological purification of waste gases of engine exhaust gases by catalytic processes
The disclosure relates to the assembly of Virus Like Particles [VLPs] using packaging native and artificial packaging signals and their use in vaccines and immunological compositions and the methods of vaccination or immunisation against human and animal viral pathogens.
"The present application relates to a method for the production of a noble metal nanomaterial comprising: (A) adding an aqueous solution of a source of noble metal ions and a reducing agent to an aqueous solution of an organic compound to form a reaction mixture, wherein the organic compound is capable of undergoing 2D planar stacking in aqueous solution; and (B) separating the noble metal nanomaterial from the reaction mixture. The present application also relates to a noble metal nanomaterial manufactured according to said method."
B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
C22C 1/04 - Making non-ferrous alloys by powder metallurgy
1 are as described herein. Also disclosed are a pharmaceutical composition containing the compound and a method of using the compound for treating cancer, such as renal cancer.
A rotary valve is provided comprising a valve housing, a valve member positioned relative to the valve housing so as to define a gap, and a compressible member located within the gap. A portion of the valve member is configured to rotate relative to the valve housing so as to vary the width of the gap between the valve member and the valve housing. As the gap width is varied,the compressible member is compressed, which subsequently alters the rate of fluid flow through the valve.In this way,the rate of fluid flow through the valve is controlled based upon the position of the portion of the valve member relative to the valve housing. Unlike known pinch valves, the valve member is configured to move along a length of the compressible member as the portion of the valve member rotates relative to the valve housing.
The invention relates to a composite material comprising cellulose. The composite material comprises a first cellulose-based material, which may be a textile or fabric, and a second cellulose-based material, which may be a film or cellulose based material or powdered cellulose-based material. The second cellulose-based material may be a sheet material comprising cellulose, such as a paper or a regenerated cellulose film. In embodiments the material is a so called "all cellulose composite" where both of the materials that are brought together are different forms of material comprising or being cellulose. For example, the different materials originate from cellulose-based feedstocks. The invention also relates to a process for preparing the composite materials of the invention utilising ionic liquids.
B32B 5/02 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by structural features of a layer comprising fibres or filaments
B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
B32B 23/10 - Layered products essentially comprising cellulosic plastic substances next to a fibrous or filamentary layer
C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material
B21D 26/02 - Shaping without cutting otherwise than by using rigid devices or tools or yieldable or resilient pads, e.g. shaping by applying fluid pressure or magnetic forces by applying fluid pressure
A steerable endoscope system includes a continuum manipulator, a plurality of syringes, and a steerable tip. The continuum manipulator includes a plurality of spaced discs and a plurality of backbones each extending through all discs. A bending movement of the continuum manipulator changes a varying linear displacement of each backbone. Each backbone is further coupled to a different one of the syringes such that the linear displacement of each backbone pushes or pulls a piston of the corresponding syringe by a varying amount. The steerable tip includes a plurality of bellows each pneumatically coupled to a different syringe such that movement of the piston of a syringe causes the corresponding bellow to inflate or deflate. Because the distal end of each bellow is fixedly coupled to the same end effector, variations in the amount of inflation or deflation on each bellow causes a bending of the steerable tip.
A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
An electrically switchable optical modulator for modulating an optical wavefront transmitted therethrough, comprising a birefringent first optical element and a birefringent second optical element each having respective ordinary and extraordinary refractive indices. A birefringent liquid crystal material is sandwiched between the first and second optical elements. The extraordinary refractive index of the liquid crystal material is electrically switchable between: a first state in which it has a first value; and, a second state in which it has a second value different from the first value. One or both of the first value and the second value is un-matched to the extraordinary refractive index of the first optical element in respect of light polarised in a first direction of linear polarisation, and is un-matched to the extraordinary refractive index of the second optical element in respect of light polarised in a second direction of linear polarisation orthogonal to the first direction.This switchably renders a relative contrast in extraordinary refractive index as between the liquid crystal material and the first and second optical elements for modulating said wavefront.
G02F 1/29 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the position or the direction of light beams, i.e. deflection
G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF LEEDS (United Kingdom)
UNIVERSITY OF YORK (United Kingdom)
Inventor
Le Grice, Stuart F.J.
Stockley, Peter G.
Twarock, Reidun
Abulwerdi, Fardokht A.
Abstract
Disclosed are methods of treating hepatitis B virus (HBV) and inhibiting replication of HBV in a mammal comprising administering to the mammal in need thereof, e.g., administering a compound selected from the group consisting of compounds P1-P29 (as described herein), or a stereoisomer or a pharmaceutically acceptable salt thereof. For example, compound P1 has the following structure: (I)
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A process for reducing microbial growth in solutions of sugars extracted from waste materials, the process comprising monitoring indicators of microbial growth in the solution in situ and administering an antimicrobial; a sugar substrate obtained by concentrating a solution of sugar treated using the process; an apparatus for extracting sugars from waste materials, the apparatus comprising a reaction vessel (10), one or more sensors (15,20) for monitoring indicators of microbial growth in the reaction vessel, a software for analysing signals from the sensor and a source of antimicrobial.
This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
A device for supporting development of a cellular deposit comprising at least one of a cell or a tissue derived from an ovary. The device comprises an inlet well, an outlet well, and an enclosed culture chamber disposed between the inlet well and the outlet well. The device further comprises an inlet channel fluidly coupling the inlet well to the culture chamber and an outlet chamber and/or at least one outlet channel fluidly coupling the culture chamber to the outlet well. At least one of the outlet chamber and the at least one outlet channel is sized to prevent passage of the cellular deposit therethrough.
A device for supporting development of a cellular deposit comprising at least one of a cell or a tissue derived from an ovary. The device comprises an inlet well, an outlet well, and an enclosed culture chamber disposed between the inlet well and the outlet well. The device further comprises an inlet channel fluidly coupling the inlet well to the culture chamber and an outlet chamber and/or at least one outlet channel fluidly coupling the culture chamber to the outlet well. At least one of the outlet chamber and the at least one outlet channel is sized to prevent passage of the cellular deposit therethrough.
This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
The present invention relates to a substrate comprising an ion-implanted layer, for example a cation, wherein the ion implanted layer has a substantially uniform distribution of the implanted ions at a significantly greater depth than previously possible, to a well-defined and sharp boundary within the substrate. The invention further comprises said substrate wherein the substrate is a silicon based substrate, such as glass. The invention also comprises the use of said material as a waveguide and the use of said material in measurement devices.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
C23C 14/28 - Vacuum evaporation by wave energy or particle radiation
C23C 14/32 - Vacuum evaporation by explosionVacuum evaporation by evaporation and subsequent ionisation of the vapours
C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
Mayo Foundation for Medical Education and Research (USA)
University of Leeds (United Kingdom)
Inventor
Vile, Richard G.
Kottke, Timothy J.
Thompson, Jill M.
Pulido, Jose S.
Melcher, Alan A.
Selby, Peter
Abstract
This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors (e.g., gliomas) within a mammal (e.g., a human) are provided.
09 - Scientific and electric apparatus and instruments
Goods & Services
Scientific teaching apparatus kit comprised of a fluid flow simulator with cascading continuous stirred tank reactor and parts and fittings therefore; scientific apparatus, namely, flow reactors and stirred tank reactors
There is provided the use of an aligned nematic elastomer to form a material having auxetic properties wherein the aligned nematic material has a mechanical Fréedericksz transition. Also provided is a method of producing an aligned nematic elastomer for said use.
C09K 19/12 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings at least two benzene rings directly linked, e.g. biphenyls
C09K 19/54 - Additives having no specific mesophase
C09K 19/04 - Liquid crystal materials characterised by the chemical structure of the liquid crystal components
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and technological services and research and design relating thereto; research and development services; industrial analysis and research services; research, design and development services in the field of foodstuffs; research relating to health, nutrition, diet and food; research into the treatment of waste materials; inspection and testing of foodstuffs; computerised food analysis services; quality control relating to the hygiene of food; organisation of clinical trials; food technology research; knowledge and technology transfer services; analysis of materials; laboratory services; laboratory testing services; scientific testing in food and food products; quality control; quality control testing; quality assurance consultancy; research and development for others; food intolerance, food analysis, food technology, food science and food safety studies; contract research services relating to food science; provision of information on food safety; information exchange services between scientists, researchers, commercial and industrial entities namely industrial analysis and research projects; provision of scientific, technological and research information; laboratory research; technical project studies; preparation of reports relating to technical or scientific research; creating, testing, implementing, developing, maintaining, updating, and providing advisory and consultancy services in relation to computer programs, computer networks, websites, web pages and mobile apps; advisory, information and consultancy services and the preparation of reports all relating to the aforesaid services. Food nutrition consultation; providing nutritional information about food; dietary and nutritional guidance; consultancy and counselling services relating to health, nutrition, diet and food; advisory services and the provision of information relating to health, nutrition, diet and food; nutritional advisory services for the purposes of promoting health and wellbeing; providing online news and information in the fields of health, nutrition, diet, food, healthcare and wellness services for the purpose of nutritional guidance via websites; providing consulting services in the fields of health, nutrition, diet and food; agricultural and horticultural advisory services relating to food; information, advisory and consultancy services and the preparation of reports, all relating to the aforesaid services.
